Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: Short- and long-term outcomes Journal Article
| Authors: | Frankfurt, O.; Ma, S.; Gordon, L.; Winter, J. N.; Horowitz, J. M.; Rademaker, A.; Weitner, B. B.; Peterson, L. C.; Altman, J. K.; Tallman, M. S.; Petrich, A.; Rosen, S. T. |
| Article Title: | Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: Short- and long-term outcomes |
| Abstract: | We investigated the safety, efficacy, and long-term outcomes of alemtuzumab and rituximab (AR) combination therapy in previously untreated patients with CLL. Thirty patients, ages 28-80 years, 47% older than 60 years, 90% Rai clinical stages II-IV, and 67% without favorable cytogenetics received AR. Based on the NCI-WG 1996 criteria, OR was 100%, with 60% CR. With CT scans OR was 70%, with 23% CR, 47% PR, and 30% SD. Sixty-seven percent of patients showed no evidence of MRD in the bone marrow by 6-color flow cytometry. Median PFS, TFS, and 5-year OS were 24.4, 50.7 months, and 80%, respectively. Grade 3/4 neutropenia and thrombocytopenia were reported in 30% and 7% of patients, respectively. CMV reactivation, asymptomatic in all but one patient, occurred in 8 patients. Immunotherapy with alemtuzumab and rituximab results in robust responses and long asymptomatic therapy-free intervals. It is well tolerated with infrequent, predictable, and easily managed complications. © 2014 Informa UK, Ltd. |
| Keywords: | adult; clinical article; aged; overall survival; fatigue; neutropenia; cancer growth; diarrhea; drug efficacy; drug safety; rituximab; cancer staging; anorexia; cancer immunotherapy; progression free survival; computer assisted tomography; drug eruption; nephrotoxicity; phase 2 clinical trial; anemia; nausea; thrombocytopenia; drug dose escalation; drug fever; prednisolone; immunotherapy; minimal residual disease; paracetamol; pancytopenia; second cancer; chronic lymphatic leukemia; bacterial infection; cytomegalovirus infection; lymphadenopathy; cytomegalovirus; alemtuzumab; cll; hypocalcemia; virus reactivation; diphenhydramine; hypertransaminasemia; very elderly; human; male; female; priority journal; article |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 56 |
| Issue: | 2 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2015-02-01 |
| Start Page: | 315 |
| End Page: | 323 |
| Language: | English |
| DOI: | 10.3109/10428194.2014.910654 |
| PROVIDER: | scopus |
| PUBMED: | 24707943 |
| DOI/URL: | |
| Notes: | Export Date: 2 April 2015 -- Source: Scopus |
